Ambit Biosciences Receives $30,000,000 Series D Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f1d5c08a-248e-4748-869e-1f8a9ea43a5a&Preview=1 - Date
6/10/2011 - Company Name
Ambit Biosciences - Mailing Address
4215 Sorrento Valley Blvd. San Diego, CA 92121 - Company Description
Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors for the treatment of cancer. - Website
http://www.ambitbio.com - Transaction Type
Venture Equity - Transaction Amount
$30,000,000 - Transaction Round
Series D - Proceeds Purposes
This recent capital raise will allow us to continue the clinical development of our lead product candidate, AC220, which is currently in a Phase 2 pivotal trial in Acute Myeloid Leukemia. This financing also provides for the continued development of our other two clinical assets, AC430 and AC480, both of which are in Phase 1 trials. - M&A Terms
- Venture Investor
Apposite Capital - Venture Investor
OrbiMed - Venture Investor
Forward Ventures - Venture Investor
MedImmune Ventures - Venture Investor
Growthworks Capital - Venture Investor
Roche Venture Fund - Venture Investor
GeneChem - Venture Investor
GIMV - Venture Investor
Radius Ventures - Venture Investor
NovaQuest - Venture Investor
Horizon Technology Finance
